Phase II Trial of Trastuzumab in Women with Advanced or Recurrent, HER2-Positive Endometrial Carcinoma: a Gynecologic Oncology Group Study

PURPOSE: This study evaluated efficacy of single-agent trastuzumab against advanced or recurrent HER2-positive endometrial carcinoma (EC), and explored predictors for HER2 amplification. PATIENTS AND METHODS: Eligible patients had measurable stage III, IV, or recurrent EC. There was no limit on prio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fleming, Gini F., Sill, Michael W., Darcy, Kathleen M., McMeekin, D. Scott, Thigpen, J. Tate, Adler, Lisa M., Berek, Jonathan S., Chapman, Julia A., DiSilvestro, Paul A., Horowitz, Ira R., Fiorica, James V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2804260/
https://ncbi.nlm.nih.gov/pubmed/19840887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2009.09.025
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados